Biotech Catalysts, Stock Hubs & U.S. Small/Mid-Cap Research
Merlintrader publishes independent educational research on U.S.-listed biotech and small- and mid-cap stocks, with daily market briefings, FDA and PDUFA tracking, catalyst calendars and dedicated company hubs across biotech, space, defense, AI, cannabis, energy and critical minerals.
Merlintrader’s Daily Briefing
Tuesday, August 4, 2026, morning edition. Prices are Monday’s New York closes unless stated. The Dow closed at a record after President Trump called off strikes on Iran and opened talks on the Strait of Hormuz, and crude gave back about five percent in the session. Palantir then delivered the quarter of the year after the bell: revenue up 93% to $1.94 billion, US commercial up 149%, full-year guidance lifted above $8.15 billion, and the shares up roughly 10% in after-hours trade. Brent has since recovered about 1.4% in Asia, the yen is still holding its intervention gains, and the September policy debate is about a hike rather than a cut. AMD and SpaceX report tonight; Friday’s payrolls report is the week’s real test.
- Indexes — The Dow Jones Industrial Average rose 693.38 points, or 1.32%, to a record close of 53,178.41. The S&P 500 gained 1.48% to 7,600.50 and the Nasdaq Composite added 2.1% to 25,913.9, both finishing near record territory.Wall Street
- Trackers — The S&P 500 fund $SPY closed at $757.67, up 1.42%; the Nasdaq-100 fund $QQQ at $700.07, up 1.76%; the Dow fund $DIA at $531.22, up 1.32%; and the small-cap fund $IWM at $296.22, up 1.72%. Breadth was with the move rather than against it.Tape
- What drove it — Trump said he had called off “massive” strikes on Iran and that negotiations would begin, with Gulf allies including Saudi Arabia pressing for diplomacy. Iran’s foreign ministry said no direct talks with Washington were under way, which is the gap the market has chosen to look through.Geopolitics
- Europe today — Pan-European futures were up 0.3% and German DAX futures 0.2% higher in early trade, both indexes within reach of record highs, with FTSE futures up 0.3%. European closing levels are not yet available.Europe
- $PLTR results — Second-quarter revenue rose 92.8% year on year to $1.94 billion against a consensus near $1.81 billion, with adjusted earnings of $0.41 a share against an estimate in the $0.33–0.35 range. GAAP operating income was $912 million at a 47% margin and adjusted operating income $1.19 billion at a 62% margin.Earnings
- US commercial — The segment that carries the story grew 149% year on year to $764 million. Management raised full-year US commercial guidance to more than $3.424 billion, at least 134% annual growth, from about $3.22 billion previously.Growth
- Guidance — Full-year 2026 revenue guidance moved up to $8.150–8.158 billion, roughly 82% growth, with adjusted operating income of $4.889–4.897 billion and adjusted free cash flow of $4.5–4.7 billion. Third-quarter revenue is guided to $2.160–2.164 billion.Outlook
- Reaction — The shares closed the regular session at $125.65, up 2.10% on 77 million shares, then traded roughly 10–12% higher after hours toward $140. After the first-quarter report the stock fell on a beat, so the guidance raise, not the beat, is what changed the response this time.After hours
- Crude — Brent fell about 5.7% on Monday to roughly $82.92 a barrel and the oil fund $USO closed at $122.12, down 5.46%. Overnight the move partly reversed: Brent was up about 1.4% at $84.93 in the Asian session as traders looked past the promise to hold fire. The energy fund $XLE closed at $58.79, down 1.28%, the only major group lower on the day.Energy
- Treasuries — The 10-year yield eased to about 4.67% as the energy premium came out. The long-bond fund $TLT closed at $82.19, down 0.07%, so the long end did not follow the belly — a term-premium signal that has nothing to do with Hormuz.Bonds
- The Fed — New York Fed President Williams told Reuters he expects inflation to fall through the second half of 2026 and further in 2027, that policy is well positioned, and that the Fed would raise rates if price pressures fail to ease. Markets still price roughly 63% odds of a September hike, and he declined to endorse or reject that pricing.Policy
- Yen — The dollar-yen pair is the live variable after last week’s coordinated Tokyo–Washington intervention, the first joint yen-buying operation since 2011. The 155 level is the next test, and pressure is rebuilding in global bond markets even as the currency holds its gains.FX
- Megacaps — $AMZN closed at $284.02, up 4.58%, crossing a $3 trillion market capitalisation on the back of Friday’s cloud numbers. $MSFT ended at $487.65, up 4.93%, and $GOOGL at $373.51, up 4.88%. $AAPL was the outlier at $303.42, down 1.78%.Big Tech
- $CRWV — CoreWeave closed at $85.76, up 19.49% on 44.6 million shares, the single largest move among large-capitalisation AI names. The company reports on August 11.AI cloud
- Semis — $NVDA closed at $206.64, up 2.93%, $AMD at $484.64, up 1.78%, $MU at $829.50, up 0.79% and $AVGO at $392.23, up 0.76%. The semiconductor fund $SMH added 0.91%, lagging the Nasdaq by more than a point.Semis
- Washington and AI — Meta, Anthropic, OpenAI and Google have been invited to meet White House officials today to discuss voluntary government safety testing of their most advanced models, following security incidents involving autonomous AI agents.Policy
Biotech Catalyst Calendar 2026
Last updated: 22 July 2026Merlintrader tracks upcoming biotech catalysts for U.S.-listed companies, including PDUFA dates, FDA decisions, clinical-trial readouts, advisory committee meetings and other regulatory milestones. Alongside each date you will find the source, company context and the key risks that can move the stock, plus links to deeper Merlintrader research when it is available. The focus is educational and risk-aware, with particular attention to small and mid-cap biotech names, where catalyst timing, cash runway and dilution risk can drive sharp moves in volatility. Dates can change and FDA decisions can arrive early or late, so always confirm an event against company filings and regulatory sources before acting on it.
Weekly Biotech Catalyst Tracker
Window covered: July 31 → September 30, 2026. Compact homepage board for unresolved FDA decisions, regulatory submissions and major clinical readouts. A prior-date item remains visible only when the regulatory outcome has not yet been publicly disclosed. October and later events are excluded from this widget.
$NRXPKETAFREEJul 29*Pending
GDUFA goal passed; public FDA outcome pendingNRx Pharmaceuticals. The FDA-assigned July 29 GDUFA goal date for the KETAFREE preservative-free IV ketamine ANDA has passed. As of the July 31 update, no approval, tentative approval or complete response had been publicly disclosed by the company, so the item remains active as an unresolved regulatory watch. This is an ANDA event, not a PDUFA for NRX-100 or NRX-101.
$REPLRP1Aug 2PDUFA
Melanoma BLA resubmissionReplimune. BLA resubmission goal date for RP1. This is a very compressed AdCom-to-PDUFA setup with elevated regulatory risk.
$MRNAmFLUSIVAAug 5PDUFA
mRNA seasonal fluModerna. Following the FDA advisory committee’s unanimous June endorsement, the BLA PDUFA for the mRNA seasonal flu vaccine candidate in adults 50+ is due August 5. Approval remains pending; the event is more of a platform and lifecycle read-through than a pure small-cap binary.
$REGNgaretosmabAugFDA
FOP ultra-rare diseaseRegeneron. BLA target action month for garetosmab in adult fibrodysplasia ossificans progressiva. Month-only calendar item.
$LNTHMK-6240Aug 13NDA
Tau PET imagingLantheus. NDA PDUFA for MK-6240 tau PET imaging in Alzheimer’s disease. Diagnostic/imaging catalyst, not a therapeutic efficacy binary.
$CAPRderamiocelAug 22Extreme risk
PDUFA after 9–3 negative efficacy voteCapricor. The BLA remains under FDA review for the treatment of DMD cardiomyopathy, but the July 29 advisory committee voted 9–3 that the available evidence did not provide substantial evidence of effectiveness. FDA is not legally bound by the vote, yet the combination of the negative panel recommendation, disputed endpoint analyses and prior CRL history makes the August 22 decision an extreme-risk regulatory event.
$RAREDTX401Aug 23BLA
GSDIa gene therapyUltragenyx. Priority Review BLA PDUFA for DTX401 in glycogen storage disease type Ia. First of two near-term Ultragenyx gene-therapy decisions.
$BIIBLeqembi IQLIKAug 24sBLA
SC starting doseBiogen / Eisai. sBLA PDUFA for once-weekly subcutaneous Leqembi starting-dose use. Large-cap Alzheimer’s lifecycle catalyst.
$JAZZZiihera comboAug 25sBLA
1L HER2+ GEAJazz Pharmaceuticals. sBLA PDUFA for Ziihera combination use in first-line HER2-positive gastroesophageal adenocarcinoma.
$GILDBIC/LENAug 27NDA
Once-daily HIV regimenGilead. NDA PDUFA for bictegravir/lenacapavir in virologically suppressed adults. Strategic HIV franchise catalyst.
$PTGXrusfertideQ3PDUFA
Polycythemia veraProtagonist / Takeda. Priority Review NDA window for rusfertide in polycythemia vera. Exact date not pinned in this compact board.
$GSKzidesamtinibSep 18NDA
ROS1+ NSCLC · acquired Nuvalent assetGSK / former Nuvalent. GSK completed its acquisition of Nuvalent on July 15 and $NUVL ceased trading. The September 18 FDA PDUFA for zidesamtinib in TKI-pretreated ROS1-positive non-small-cell lung cancer remains active, but it is now a large-cap $GSK regulatory catalyst rather than an $NUVL trading event.
$RAREUX111Sep 19Risk
Sanfilippo A gene therapyUltragenyx. Resubmitted BLA PDUFA for UX111 in Sanfilippo syndrome type A. CMC and facility risk remain the key swing factors.
$IONSzilganersenSep 22NDA
Alexander diseaseIonis. NDA PDUFA for zilganersen in Alexander disease. Rare neurological disease Priority Review event.
$BFRIAmeluz PDTSep 28sNDA
Superficial BCC expansionBiofrontera. PDUFA for Ameluz photodynamic therapy sNDA seeking expansion into superficial basal cell carcinoma. Small-cap liquidity can amplify reaction.
$SRRKapitegromabSep 30BLA
Spinal muscular atrophyScholar Rock. BLA PDUFA for apitegromab in spinal muscular atrophy. Manufacturing and fill-finish facility status remain key watch items.
$ROIVbrepocitinibQ3NDA
DermatomyositisPriovant / Roivant. NDA Priority Review window for brepocitinib in dermatomyositis. Company has pointed to potential launch timing by end-September if approved.
$QUREAMT-130Q3BLA
Huntington’s AA pathuniQure. Planned BLA submission for AMT-130 in Huntington’s disease. Not a PDUFA, but one of the most important regulatory-pathway events in the quarter.
$SLNdivesiranAugData
SANRECO Phase 2 PVSilence Therapeutics. SANRECO Phase 2 topline data for divesiran in polycythemia vera. Important read-through alongside $PTGX / Takeda rusfertide.
$IMMXNXC-201Q3Data
AL amyloidosisImmix Biopharma. NEXICART-2 topline data for NXC-201 in relapsed/refractory AL amyloidosis. BLA-enabling study, high-volatility small-cap setup.
$KPTIselinexorNearData
Endometrial cancer Ph3Karyopharm. XPORT-EC-042 Phase 3 topline data for selinexor in endometrial cancer. Treat as near-term until released or formally delayed.
$KODDAYBREAKQ3Data
Wet AMD Phase 3Kodiak Sciences. DAYBREAK Phase 3 topline data for tarcocimab / KSI-501 in wet AMD. Watch efficacy, durability, dosing interval and safety.
$ALMSenvudeucitinibQ3Data
SLE Phase 2bAlumis. LUMUS Phase 2b readout for envudeucitinib in systemic lupus erythematosus. Autoimmune data can be noisy; dose response matters.
$IVVDVYD2311Q3Data
DECLARATION pivotalInvivyd. DECLARATION pivotal / Phase 3 topline data for VYD2311. COVID-antibody sentiment can be unstable, but pivotal data can still move the name.
$MPLTML-007C-MAMid-AugData
ZEPHYR schizophrenia Ph2MapLight Therapeutics. Phase 2 ZEPHYR topline results for ML-007C-MA in schizophrenia. CNS readout with potentially sharp binary reaction.
$AMLXavexitideQ3Ph3
PBH pivotal LUCIDITYAmylyx. Phase 3 LUCIDITY topline results for avexitide in post-bariatric hypoglycemia. One of the clearest Phase 3 clinical binaries of the quarter.
$PHVSdeucrictibant ERQ3Ph3
HAE prophylaxis Ph3Pharvaris. Phase 3 CHAPTER-3 data for extended-release deucrictibant as prophylaxis for hereditary angioedema. Major HAE readout.
$SYRESPY003Q3Data
IBD / UC Phase 2Spyre Therapeutics. Phase 2 SKYLINE Part A topline data for SPY003 in inflammatory bowel disease and ulcerative colitis.
$VERATrutakna / ataciceptQ3eGFR
ORIGIN 3 follow-upVera Therapeutics. ORIGIN 3 eGFR analysis following accelerated approval. Not another approval decision, but important for durability and confirmatory confidence.
$OCGNOCU410STQ3Data
Stargardt interim analysisOcugen. Interim OCU410ST analysis after 24 patients complete eight months of follow-up in Stargardt disease. Small-cap ophthalmology catalyst.
$XENEazetukalnerQ3NDA
Focal-onset seizures filingXenon. Expected NDA submission for azetukalner in focal-onset seizures. Filing confirmation would set up future FDA acceptance and PDUFA timing.
$BBIOinfigratinibQ3NDA
Achondroplasia filingBridgeBio. Expected NDA submission for infigratinib in achondroplasia. Submission timing and acceptance will define the next regulatory leg.
$CLNNCNM-Au8Q3NDA
ALS accelerated pathwayClene. Targeted NDA submission for CNM-Au8 in ALS through an accelerated pathway. Very high regulatory strategy risk because submission does not guarantee acceptance.
$OCGNOCU400Q3BLA
Rolling BLA startOcugen. Expected start of rolling BLA submission for OCU400 in retinitis pigmentosa. Filing progress, manufacturing and future acceptance are the next watch items.
$MLTXsonelokimabLate SepBLA
HS filing watchMoonLake. Planned BLA submission for sonelokimab in hidradenitis suppurativa around the end of September. Acceptance would create the next formal FDA calendar item.
Most attention-worthy watchlist
Board rule
Only unresolved catalysts through September are shown. Past events are removed once an outcome is publicly confirmed; a passed target date may remain visible when the FDA action has not yet been disclosed. $NRXP therefore remains marked Pending after its July 29 KETAFREE GDUFA goal date. October and later events are intentionally excluded. $NUVL was acquired by GSK and ceased trading, so the September zidesamtinib catalyst is shown under $GSK. Events carrying only Q3 guidance must be rechecked against company filings before trading around them.
Biotech Catalyst Lookup
Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.
Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.
- Biotech Radar July 29, 2026: PolyPid Gets Priority Review, Processa Resets Around VT-7208, TScan Starts Phase 3 — $PYPD $PCSA $TCRX
- $OTLK After FDA Approval: The Warrant–ATM–Reverse Split Spiral Retail Cannot Fight on Equal Terms
- Biotech Radar July 28, 2026: Kiniksa Rerates, Nautilus Pushes Voyager Shipments to Mid-2027 and Alkermes Expands Its Sleep Franchise — $KNSA $NAUT $ALKS
- $MSOS $TLRY $CGC $ACB: After the DEA Hearing, the Cannabis Trade Moves Into the Shadows
- Biotech Radar July 27, 2026: Entera Bio ($ENTX), Freenome ($FRNM), Sarepta Therapeutics ($SRPT) and Legend Biotech ($LEGN)
- MapLight Therapeutics ($MPLT): Why the Stock Collapsed After a “Positive” Schizophrenia Trial
- $DPRO, $AXON, $RCAT, $ONDS: Why Small-Town America Is the Hardest Drone Market to Sell — The Five Barriers Explained
- $SMMT, $MRK: Ivonescimab’s China-First Test
- FDA Showdown Week: Capricor and Replimune Face Back-to-Back AdCom Tests — $CAPR $REPL
- Weekly Market Recap & Week Ahead: AI Cash Burn, Oil Shock, Fed Week and FDA AdComs — $SPY $QQQ $XBI
- Golden Dome Enters the Procurement Era: 108 Tracking Satellites, the FY2027 Funding Fight and What It Means for $LHX $RKLB $LMT $NOC
- Cannabis News Today: DEA Rescheduling, U.S. Hemp and $ACB $TLRY $CRON $CGC
- Biotech Radar July 22, 2026: BridgeBio, Curis, Monopar and Others — $BBIO $CRIS $MNPR
- Why The Critical-Minerals Race Is Won In The Midstream, Not The Mine ($UAMY, $MP, $USAR, $TMC)
- Priority Review Vouchers Explained: How an FDA Approval Becomes $180-205 Million in Cash, With $RCKT and $DNLI as Worked Examples · $XBI $IBB
- Betting on the FDA: How Kalshi’s Biotech Prediction Markets Work, and What They Mean for $XBI, $IBB and the Sector



















